ABSTRACT
INTRODUCTION: Transverse colon cancer (TCC) is poorly studied, and TCC cases are often excluded from large prospective randomized trials because of their complexity and their potentially high complication rate. The best surgical approach for TCC has yet to be established. The aim of this large retrospective multicenter Italian series is to investigate the advantages and disadvantages of both hemicolectomy and transverse colectomy in order to identify the best surgical approach. MATERIALS AND METHODS: This was a retrospective cohort study of patients with mid-transverse colon cancer treated with a segmental colon resection or an extended hemicolectomy (right or left) between 2006 and 2016 in 28 high-volume (more than 70 procedures/year) Italian referral centers for colorectal surgery. RESULTS: The study included 1529 patients, 388 of whom underwent a segmental resection while 1141 underwent an extended resection. A higher number of complications has been reported in the segmental group than in the extended group (30.1% versus 23.6%; p 0.010). In 42 cases the main complication was the anastomotic leak (4.4% versus 2.2%; p 0.020). Recovery outcomes also showed statistical differences: time to first flatus (p 0.014), time to first mobilization (p 0.040), and overall hospital stay (p < 0.001) were significantly shorter in the extended group. Even if overall survival were similar between the groups (95.1% versus 97%; p 0.384), 3-year disease-free survival worsened after segmental resection (78.1% versus 86.2%; p 0.001). CONCLUSIONS: According to our results, an extended right colon resection for TCC seems to be surgically safer and more oncologically valid.
Subject(s)
Anastomotic Leak/epidemiology , Colectomy/methods , Colon, Transverse/surgery , Colonic Neoplasms/surgery , Length of Stay/statistics & numerical data , Surgical Wound Infection/epidemiology , Aged , Aged, 80 and over , Colon, Transverse/pathology , Colonic Neoplasms/pathology , Disease-Free Survival , Female , Humans , Italy/epidemiology , Male , Middle Aged , Neoplasm Staging , Postoperative Complications/epidemiology , Retrospective Studies , Survival Rate , Time FactorsABSTRACT
OBJECTIVE: Malignant bowel obstruction (MBO) is usually a pre-terminal event in patients with ovarian cancer. However, because of the lack of data in literature, decisions around surgical intervention, non-resectional procedures, or medical treatment of MBO in patients with ovarian cancer cannot be lightly undertaken. We analyzed medical and surgical procedures, performance status, nutritional status, cachexia, and their prognostic value in this group of patients. METHODS: We retrospectively selected all consecutive patients with recurrent ovarian cancer who received medical or surgical treatment for MBO between October 2008 and January 2014 at the Academic Department of Gynecological Oncology of Mauriziano Hospital of Turin (Italy). RESULTS: We found 40 patients: 18 of them underwent medical treatment and 22 of them were submitted to surgery. In the group of surgery, the hospitalization was shorter (p 0.02), the pain reduction was more effective (p 0.001), the number of chemotherapy lines was higher (p 0.03), and re-obstruction was more rare (p 0.02). Between the two groups, we did not find any differences in post-palliation episodes of vomit (p 0.83), type of diet (p 0.34), ability to return home (p 0.72), and death setting (p 0.28). Median survival after palliation was longer in the group of surgery (p 0.025). Cachexia, low performance status, and poor nutritional status were significant predictors of worse survival after MBO, independently by the treatment. CONCLUSIONS: Surgery has to be considered in patients without serious contraindications; otherwise, a medical protocol, including antisecretory drugs, is the standard of care in frail patients.
Subject(s)
Intestinal Obstruction/surgery , Neoplasms, Glandular and Epithelial/complications , Ovarian Neoplasms/complications , Palliative Care/methods , Adult , Aged , Cachexia/drug therapy , Carcinoma, Ovarian Epithelial , Female , Humans , Intestinal Obstruction/etiology , Italy , Middle Aged , Neoplasms, Glandular and Epithelial/mortality , Ovarian Neoplasms/mortality , Pain/drug therapy , Prognosis , Recurrence , Retrospective Studies , Young AdultABSTRACT
PURPOSE: The lymph node status is one of the strongest prognostic determinants in rectal cancers. After chemoradiotherapy (CRT), lymph nodes are difficult to detect. This study aims to evaluate the feasibility of lymph node mapping in the mesorectum after CRT to analyze the pattern of metastasis spread and to assess the reliability of blue dye injection in sentinel lymph node detection. METHOD: Ten patients with cN+ mid/low RCs after CRT were prospectively enrolled. The protocol scheduled intraoperative blue dye injection, surgery, and specimen examination with fat clearance technique. The mesorectum was divided into three equal "levels" (upper, middle, and lower); each level was divided into three equal "sectors" (right anterolateral, posterior, and left anterolateral). Lymph nodes were defined "small" if ≤5 mm. RESULTS: Two hundred seventy-six lymph nodes were retrieved in ten patients; 76.5 % were small lymph nodes. Six patients were pN+ (33 metastatic lymph nodes, 76 % small); small lymph node analysis upstaged one patient from N0 to N1 and four patients from N1 to N2. Metastasis distribution across sectors was continuous, without "skip sectors." The blue dye detected the sentinel lymph node in all patients; in half of the cases, it was out of the tumor sector. Blue dye identified 69.7 % of metastatic lymph nodes; its sensitivity decreased together with the metastatic deposit size (84 % macrometastases, 28.6 % micrometastases, 0 % occult tumor cells; p = 0.004). CONCLUSION: The fat clearance technique should be the standard pathological examination in patients with RCs after CRT; N staging was improved by small lymph node identification. Lymph node metastases have a continuous spread through mesorectal sectors. Blue dye injection is effective in sentinel lymph node detection.
Subject(s)
Chemoradiotherapy , Lymph Nodes/pathology , Lymphatic Metastasis/pathology , Neoadjuvant Therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/therapy , Aged , Aged, 80 and over , Humans , Intraoperative Care , Male , Middle Aged , Neoplasm Staging , Rectal Neoplasms/drug therapy , Rectal Neoplasms/radiotherapyABSTRACT
Analyzing the recent high-quality genome sequence of the domestic dog (Canis lupus familiaris), we deduced for the first time in a mammalian species belonging to Carnivora order, the genomic structure and the putative origin of the TRG locus. New variable (TRGV), joining (TRGJ) and constant (TRGC) genes for a total of 40 are organized into eight cassettes aligned in tandem in the same transcriptional orientation, each containing the basic recombinational unit V-J-J-C, except for a J-J-C cassette, that lacks the V gene and occupies the 3' end of the locus. Amphiphysin (AMPH) and related to steroidogenic acute regulatory protein D3-N-terminal like (STARD3NL) genes flank, respectively, the 5' and 3' ends of the canine TRG locus that spans about 460kb. Moreover LINE1 elements, evenly distributed along the entire sequence, significantly (20.59%) contribute to the architecture of the dog TRG locus. Eight of the 16 TRGV genes are functional and belong to 4 different subgroups. Canine TRGJ genes are two for each cassette and only seven out of 16 are functional. The germline configuration and the exon-intron organization of the 8 TRGC genes was determined, six of them resulting functional. The dot plot similarity genomic comparison of human, mouse and dog TRG loci highlighted the occurrence of reiterated duplications of the cassettes during the dog TRG locus evolution. On the other hand the low ratio of functional genes to the total number of canine TRG genes (21/40), suggest that there is no correlation between the extensive duplications of the cassettes and a need for new functional genes. Furthermore the comparison revealed that the TRGC6, C7 and C8 genes are highly related across species suggesting these existed before the primate-rodent-canidae lineages diverged.
Subject(s)
Dogs/genetics , Receptors, Antigen, T-Cell, gamma-delta/genetics , Amino Acid Sequence , Animals , Chromosome Mapping , Evolution, Molecular , Exons , Genome , Humans , Long Interspersed Nucleotide Elements/genetics , Mice , Models, Genetic , Molecular Sequence Data , Mutagenesis, Insertional , Sequence Analysis, DNA , Sequence Homology, Amino Acid , Species SpecificityABSTRACT
BACKGROUND: The disadvantages of D2 gastrectomy have been mostly related to splenopancreatectomy. Unlike two large European trials, we have recently showed the safety of D2 dissection with pancreas preservation in a one-arm phase I-II trial. This new randomised trial was set up to compare post-operative morbidity and mortality and survival after D1 and D2 gastrectomy among the same experienced centres that participated into the previous trial. METHODS: In a prospective multicenter randomised trial, D1 gastrectomy was compared to D2 gastrectomy. Central randomisation was performed following a staging laparotomy in 162 patients with potentially curable gastric cancer. FINDINGS: Of 162 patients randomised, 76 were allocated to D1 and 86 to D2 gastrectomy. The two groups were comparable for age, sex, site, TNM stage of tumours, and type of resection performed. The overall post-operative morbidity rate was 13.6%. Complications developed in 10.5% of patients after D1 and in 16.3% of patients after D2 gastrectomy. This difference was not statistically significant (p<0.29). Reoperation rate was 3.4% after D2 and 2.6% after D1 resection. Post-operative mortality rate was 0.6% (one death); it was 1.3% after D1 and 0% after D2 gastrectomy. INTERPRETATION: Our preliminary data confirm that in very experienced centres morbidity and mortality after extended gastrectomy can be as low as those showed by Japanese authors. They also suggest that D2 gastrectomies with pancreas preservation are not followed by significantly higher morbidity and mortality than D1 resections.
Subject(s)
Gastrectomy/methods , Lymph Node Excision/methods , Postoperative Complications , Stomach Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Neoplasm Staging , Prospective Studies , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Survival AnalysisABSTRACT
BACKGROUND: The aim of this study was to assess the feasibility and safety of laparoscopic surgery for colorectal diseases. METHODS: A retrospective review was undertaken of all patients undergoing a laparoscopic colorectal procedure (LCP) for large bowel disease. All operations were performed by a single experienced team. Patients were divided chronologically into three consecutive groups (G1, G2, and G3). Data collection included the incidence and cause of both "proper" and "mandatory" conversions to laparotomy, the incidence and type of early and late postoperative complications, incidence of operative mortality, and the length of hospital stay. The incidences of conversion to laparotomy and of early and late postoperative complications were also determined as related to diagnosis, type of LCP attempted, and chronological group. RESULTS: Between January 1996 and December 2001, a total of 108 patients (49 men and 59 women) with a mean age of 65.1 years underwent an LCP for colorectal disease. Proper conversion to open surgery was necessary in five patients (4.6%), whereas a mandatory conversion was needed in 10 with patients advanced cancer (9.2%). The overall morbidity rate was 11.9%. There were no anastomotic leaks. In two patients (1.85%) developed a complication requiring reoperation. Postoperative mortality was nil. Mean postoperative hospital stay was 7.2 days. The rates of conversion and of early and late complications decreased through the three chronological periods. No trocar site recurrences were observed in the cancer patients. CONCLUSION: Laparoscopic colorectal surgery performed in experienced centers is safe; the observed morbidity and mortality rates are low and acceptable and compare favorably to those observed after standard open surgery.
Subject(s)
Colonic Diseases/surgery , Laparoscopy/statistics & numerical data , Rectal Diseases/surgery , Aged , Anastomosis, Surgical/statistics & numerical data , Colectomy/methods , Colectomy/statistics & numerical data , Colorectal Neoplasms/surgery , Diverticulitis, Colonic/surgery , Female , Follow-Up Studies , Humans , Intraoperative Complications/epidemiology , Italy/epidemiology , Laparotomy/statistics & numerical data , Length of Stay/statistics & numerical data , Male , Middle Aged , Neoplasm Recurrence, Local , Postoperative Complications/epidemiology , Retrospective Studies , Survival Rate , Treatment OutcomeABSTRACT
The adjuvant chemotherapy (A.C.) is considered as a complementary treatment in patients who underwent radical surgery for gastric cancer, with complete removal of the tumor and absence of macroscopically detectable metastasis. This treatment is generally started within 4-6 weeks after the operation. The indication to A.C. is related practically only to the stage of the disease, due to the fact that no other prognostic factors of an increased risk of relapse have been detected. Two metanalysis have been recently published by Earle (1998) and Floriani (1998); both the two have recognized a possible effective role of the CA for Gastric Cancer. Naturally these "impressions" of efficacy documented by these two metanalysis should be confirmed through new trials with larger recruitment. In these new trials the new generation schedules (weekly PELF, ECF plus 5-FU), which showed an increased response for advanced disease, should be administered.
Subject(s)
Stomach Neoplasms/drug therapy , Stomach Neoplasms/surgery , Chemotherapy, Adjuvant , HumansABSTRACT
The formation of adhesions after abdominal surgery is a very frequent event, often burdened by complications. Different techniques and materials have been tested in order to reduce peritoneal damage and the onset of adhesions. While the introduction of improved surgical techniques has been decisive, the use of drugs and irritating solutions has not produced significant results. Promising results have been obtained by the use of barrier systems that allow the peritoneal surfaces to be mechanically separated during healing and re-epithelialization: Interceed (TC7)--Absorbable Adhesion Barrier--appears to be the most appropriate material for this purpose at present, given that it has been demonstrated to be of use in reducing both the incidence and extent of adhesions. The use of this material in general surgery over the past to years or so appears to the authors to be indicated in the event of secondary abdominal surgery with detachment and extensive peritoneal damage, and in more restricted surgery performed on the true pelvis in women of child-bearing age.
Subject(s)
Abdomen/surgery , Peritoneal Diseases , Postoperative Complications , Tissue Adhesions , Adult , Cellulose, Oxidized/administration & dosage , Fallopian Tube Diseases/etiology , Fallopian Tube Diseases/prevention & control , Female , Humans , Infertility, Female/etiology , Infertility, Female/prevention & control , Male , Peritoneal Diseases/prevention & control , Peritoneal Diseases/therapy , Polytetrafluoroethylene/administration & dosage , Tissue Adhesions/prevention & control , Tissue Adhesions/therapyABSTRACT
There is no doubt that a child is capable of making statements just as any other person is, nevertheless, in addition to the need, which takes priority in some cases, of knowing how to correctly understand his way of expressing himself in order to avoid distorted interpretations, one cannot ignore the fact that his testimony may often imply delicate psychological problems for which the law must bear responsibility, on one hand to adequately protect the emotional integrity of the child and on the other to safeguard the defendant from accusations that could be the result of imagination or biased knowingly or unknowingly by third parties, particularly from within the family circle.